Intas Pharma signs licensing pact with mAbxience for etanercept biosimilar

Intas Pharmaceuticals has signed an exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for biosimilar for Etanercept. Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action, that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases. According to IQVIA, global sales of Etanercept for 12 months ending June 2023 is $11B.

In the partnership arrangement, Intas receives exclusive rights to commercialise Etanercept biosimilars through its affiliates for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the US. mAbxience will be responsible for the development, manufacturing, and supply of Etanercept biosimilar from its good manufacturing practices (GMP) approved facilities.

The financial terms of the transaction remain confidential.